George A. Limbeck

Hepatorenal glycogenosis (type I glycogenosis) and carcinoma of the liver

The second reported example of malignant hepatoma developing in a patient with type I glycogen storage disease is presented. Details of the clinical course and of the ultrastructural and biochemical characteristics of the tumor are described.

Studies of anabolic steroids. VI. Effect of prolonged administration of oxandrolone on growth in children and adolescents with gonadal dysgenesis.

Twenty-five patients with Turner Syndrome were treated with oxandrolone for six or more months. Mean growth velocity for the first year of treatment was significantly greater than pretreatment control growth velocity. Overall, there was no excessive skeletal maturation. Mean “final” height in nine XO patients (146.4 cm) was significantly greater than mean adult height of an estrogen-treated control group (140.3 cm), while that for five mosaic patients (148.2 cm) was not significantly different from a mean untreated mosaic adult height (145.2cm).

Studies of anabolic steroids: VIII. Adult stature of males with Down syndrome treated with oxandrolone during childhood*

OXANDROLONE has been shown to be effective in increasing growth velocity in children. 1-3 There still remains concern, however, about using the drug as a growth-promoting agent for fear that it may cause disproportionately rapid increase in epiphysial maturation such that eventual adult height attainment would be reduced. This brief communication addresses itself to this issue. Several years ago we published the results of a controlled study 4 wherein oxandrolone was administered to two groups of children with Down syndrome; a separate group of children with the same disorder served as a control group. Group A received oxandrolone in doses of 0.5 mg/kg/day for one year and Group B, 0.25 mg/kg/day for two years. ~In that study a significant increase in height without excessive acceleration of bone age was observed in the oxandrolone-treated groups both during the periods of therapy and at three years after initiation (one or two years after termination) of the therapy. The purpose of this paper is to present follow-up data concerning the adult height attainment of these

Studies on tyrosine-α-ketoglutarate transaminase from bovine thyroid and liver tissue

Abstract 1. 1.This paper describes the purification and characteristics of tyrosine-α-ketoglutarate transaminase ( l -tyrosine:2-oxoglutarate aminotransferase, EC 2.6.1.5) from bovine thyroid tissue. The most active preparations appeared to be more than 80% homogeneous on the basis of ultracentrifugal and immunoelectrophoretic analysis. 2. 2.Bovine thyroid tyrosine-α-ketoglutarate transaminase was compared with the same enzyme isolated from bovine liver and found to be similar with respect to heat tolerance, pH optima, substrate affinity, and response to most inhibitors. Immunologically the proteins appeared to be identical. 3. 3.The only difference between the two enzymes was the effect of diiodotyrosine. Diiodotyrosine did not inhibit thyroid transaminase and would partially protect it against inhibition by the sulfhydryl inhibitor, p -chloromercuriphenylsulfonic acid. On the other hand, diiodotyrosine inhibited liver transaminase 50% at 2.5 mM concentration and did not protect it from the inhibitory effect of p -chloromercuriphenylsulfonic acid. 4. 4.Both thyroid and liver transaminase utilized tyrosine and monoiodotyrosine as substrates but used diiodotyrosine poorly.